Navigation Links
Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile
Date:8/5/2014

ROCKVILLE, Md., Aug. 5, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today announced that, with a new multi-service agreement in place, the Company is on track to initiate Phase Ia and Ib clinical trials of SYN-004 for the prevention of Clostridium difficile (C. difficile) during the fourth quarter of 2014. The Company has entered into an agreement with Evonik for oral formulation development, analytical services, and clinical drug manufacturing in accordance to GMP guidelines, of the Company's proprietary oral beta-lactamase enzyme, SYN-004, for use in the planned clinical trials. Evonik plans to formulate and encapsulate enterically coated SYN-004 for oral delivery using material generated by Synthetic Biologics' API manufacturer FUJIFILM Diosynth Biotechnologies UK Limited.

SYN-004 is designed as the first and only prophylactic treatment intended to prevent the development of C. difficile infections, by binding with and neutralizing certain intravenous (IV) beta-lactam antibiotics in the gut. SYN-004 is intended to block the effects of antibiotics within the gastrointestinal tract, maintaining the natural balance of bacterial flora (the gut microbiome), potentially preventing the 1.1 million C. difficile infections in the U.S. each year1.

"SYN-004 has the potential to have a significant impact on mitigating the effects of C. difficile, a major public health issue, and we are thrilled to be advancing rapidly toward the clinic with our novel and differentiated approach," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "While we await the topline results of the ongoing toxicology study, we are pleased to have begun working with our strategic partner Evonik, to optimize
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 23, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... first quarter 2015 results before the Nasdaq market opens ... a live conference call and webcast to discuss its financial ... 30, 2015 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1906 (US) or 785-424-1825 (International) ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)...  Metanome, Inc., an industry leader in comprehensive ... its name to Diversigen, Inc.  The name was ... commercial source for the myriad of services and ... opportunities of the microbiome.  From the wide diversity ... those that are difficult to handle, such as ...
(Date:4/23/2015)... April 23, 2015 Delpor, Inc. (Delpor), ... that the United States Patent and Trademark Office has ... NANOPOR™ technology. US Pat. No. 8,986,727 was ... drug delivery device for the sustained release ... technology for the sustained (zero-order) release of large and ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... with minimal patient discomfort, SPOKANE, Wash., Nov. ... launch of the ComforTen(TM) Multiple Skin,Test System, its ... steel 1.2mm lancet tips, which create minimal skin ... 10-test, self-loading,surgical steel testing device on the market. ...
... NEW YORK, Nov. 9 Lev Pharmaceuticals, Inc.,(OTC Bulletin Board: LEVP.OB) today announced ... 13, 2007, at 1:00,p.m. Eastern Time (ET), in conjunction with the release of ... financial results at 7:00 a.m. ET on Tuesday, November 13,2007. DATE: ... 2007 TIME: ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... ended September 30, 2007 financial results after the ... Cadence management will host a conference call and ...
Cached Biology Technology:HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 2HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device 3Lev Pharmaceuticals Invites You to Participate in its Q3'07 Earnings Results Conference Call and Webcast 2Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results 2
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... Minn. , March 17, 2015 ... technology company specializing in clinical study management systems, ... be in attendance at ARENA,s Outsourcing in Clinical ... NC.  This event provides an excellent forum for ... easy-to-use, flexible and affordable software-as-a-service (SaaS) eClinical technology ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... January 21, JoVE, the Journal of Visualized Experiments ... that explored one of the most intriguing research questions ... The protocol, titled Conducting Miller-Urey Experiments, is comprised of ... by Dr. Stanley Miller and Dr. Harold Urey in ...
... in the early stages of multiple sclerosis (MS), low levels ... and hasten its progression, according to a new study led ... with Bayer HealthCare. The findings suggest that patients in the ... increasing their vitamin D intake. "Because low vitamin D ...
... longs fora master key that allows them to escape. A study ... how a protein that promotes tumor growth also enables cancer cells ... a blood or lymphatic vessel, a cancer cell is imprisoned in ... tumor cell,s master key. It loosens connections between endothelial cells that ...
Cached Biology News:A 21st century adaptation of the Miller-Urey origin of life experiments 2Boosting vitamin D could slow progression, reduce severity of multiple sclerosis 2FAK helps tumor cells enter the bloodstream 2
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... workstation automates a wide array of research ... Sample Preparation to Bio-Molecular and Cell Based ... the Caliper Sciclone enables numerous combinations of ... the needs of a given application, and ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
Biology Products: